FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-028									
- 1	Fatimated average	hurdon									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	.,				ors	Section	30(h)	of the i	nvestme	ent Co	mpany Act	of 1940						
1. Name and Address of Reporting Person*  BELL LEONARD				<u>AI</u>	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN								Relationship of Reportin (Check all applicable)     X Director			10% Owner		
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 07/27/2011								X	X Officer (give title below) Other (specify below)  CEO			
(Street) CHESHIRE CT 06410 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Indivi Line)	-,				
		Tabl	e I - No	on-Deriva	ative	Seci	uritie	s Ac	quired	, Dis	sposed o	f, or E	enefic	ially (	Owne	ed		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day					Execution Da		Date,			4. Securities Acquired (A) o			and 5) Sec Ber Ow Rep		ount of ities icially d Following ted action(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$.0001 per share 07/27/20					011		Code	v	2,285 <sup>(1)</sup>	(D) PIIC		27 <sup>(2)</sup>	(Instr. 3 and 4) 1,820,087		D			
		Та	ıble II -								osed of, convertib				vned			•
L. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		I. Fransaction Code (Instr. 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expirati (Month/	on Da		7. Title Amoun Securit Underly Derivat Securit and 4)	nt of ties ying	Deriv Secu	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction( (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

- 1. These sales were made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$57.25 \$57.27. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Date Exercisable Expiration

<u>/s/ Leonard Bell</u>

of Shares

Title

07/28/2011

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(D)